The Effect of Cell Aggregation on Gene Expression of Pluripotent Embryonal Carcinoma Cells
Ontology highlight
ABSTRACT:
ORGANISM(S): Mus musculus
PROVIDER: GSE4085 | GEO | 2006/01/24
SECONDARY ACCESSION(S): PRJNA95237
REPOSITORIES: GEO
Similar Datasets
Project description:Investigation of very early events required for initiating differentiation of pluripotent embryonal carcinoma cells - the effect of cell aggregation on gene expression. Experiment Overall Design: this experiment include 4 samples and 24 replicates
2008-06-12 | E-GEOD-4085 | biostudies-arrayexpress
Project description:Here we perfomed the Teratoma assay for a normal human embryonic stem cell line (H9(+Dox)), a human embryonic stem cell line with a mesendodermal differentiation bias (H9Hyb), a normal human induced pluripotent stem cell line (LU07), a human induced pluripotent stem cell line with reactivated transgenes (LU07+Dox) and a human embryonal carcinoma cell line (EC) and anayzed their gene expression. The ability to form teratomas in vivo containing multiple somatic cell types is regarded as functional evidence of pluripotency for human pluripotent stem cells (hPSCs). Since the Teratoma assay is animal-dependent, laborious and only qualitative, the PluriTest and the hPSC ScoreCard assay have been developed as in vitro alternatives. Here we compared normal hPSCs, induced hPSCs (hiPSCs) with reactivated reprogramming transgenes and human embryonal carcinoma (hEC) cells in these assays. While normal hPSCs gave rise to typical teratomas, the xenografts of the hEC cells and the hiPSCs with reactivated reprogramming transgenes were largely undifferentiated and malignant. The hPSC ScoreCard assay confirmed the line-specific differentiation propensities in vitro. However, when undifferentiated cells were analysed with PluriTest only hEC cells were identified as abnormal whereas all other cell lines were indistinguishable and resembled normal hPSCs. Our results indicate that pluripotency assays are best selected on the basis of intended downstream applications.
2017-02-24 | GSE95285 | GEO
Project description:Here we analyzed undifferentiated cells and perfomed the Teratoma assay for a normal human embryonic stem cell line (H9(+Dox)), a human embryonic stem cell line with a mesendodermal differentiation bias (H9Hyb), a normal human induced pluripotent stem cell line (LU07), a human induced pluripotent stem cell line with reactivated transgenes (LU07+Dox) and a human embryonal carcinoma cell line (EC). The ability to form teratomas in vivo containing multiple somatic cell types is regarded as functional evidence of pluripotency for human pluripotent stem cells (hPSCs). Since the Teratoma assay is animal-dependent, laborious and only qualitative, the PluriTest and the hPSC ScoreCard assay have been developed as in vitro alternatives. Here we compared normal hPSCs, induced hPSCs (hiPSCs) with reactivated reprogramming transgenes and human embryonal carcinoma (hEC) cells in these assays. While normal hPSCs gave rise to typical teratomas, the xenografts of the hEC cells and the hiPSCs with reactivated reprogramming transgenes were largely undifferentiated and malignant. The hPSC ScoreCard assay confirmed the line-specific differentiation propensities in vitro. However, when undifferentiated cells were analysed with PluriTest only hEC cells were identified as abnormal whereas all other cell lines were indistinguishable and resembled normal hPSCs. Our results indicate that pluripotency assays are best selected on the basis of intended downstream applications.
2017-02-24 | GSE95284 | GEO
Project description:EC cells derived pluripotent stem cells could prolong the development of tetraploid aggregated mice; and the increased pluripotecny of EC cells derived pluripotent stem cells coincided with the recovery of many critical genes. Therefore, EC cells derived pluripotent stem cells were really the intermediates between EC cells and ES cells. And they had specific molecular characteristics, which may account for the improved pluripotency observed. We took use of microarray method to screen out the differentially expressed genes during the reprogarmming of EC cells; and the investigation of these genes may provide us with more about the transition between tumorigenesis and pluripotency.
2009-10-23 | GSE18691 | GEO
Project description:Expression profile for undifferentiated F9 Embryonal Carcinoma cell line Keywords: expression profile
2008-02-27 | GSE10606 | GEO
Project description:Acute hypersensitivity of pluripotent testicular cancer-derived embryonal carcinoma to low-dose 5-aza deoxycytidine
| PRJNA182504 | ENA
Project description:Gene expression profiles of undifferentiated mouse embryonal carcinoma cell strains (P19, P19CL6, and 4 P19CL6 sublines) were obtained, using Affymetrix GeneChip Mouse Genome 430A and 430B. Heart diseases such as cardiac infarction damage cardiomyocytes and consequently lead to significant loss of the contractile capacity of the heart. To repair functions of the injured heart, a great deal of research has attempted to develop regenerative medicine using pluripotent stem cell-based cardiomyocytes as cell therapy products. However, the efficiency of the current methods available for the cardiac differentiation of stem cells is insufficient for clinical settings. A comprehensive understanding of the mechanism involved in the cardiac differentiation of stem cells is necessary to improve the differentiation efficiency. To identify genes assosiated with cardiomyogenic potential, we isolated P19CL6 cell sublines possessing distinct properties in cardiomyogenesis and comprared their transcriptome profiles with those of mouse embryonal carcinoma P19 and P19CL6 cells.
2011-01-26 | GSE26875 | GEO
Project description:Expression data of undifferentiated cells and xenografts of human pluripotent stem cells and embryonal carcinoma cells
| PRJNA376560 | ENA
Project description:Gene expression profiles of undifferentiated mouse embryonal carcinoma cell strains (P19, P19CL6, and 4 P19CL6 sublines) were obtained, using Affymetrix GeneChip Mouse Genome 430A and 430B. Heart diseases such as cardiac infarction damage cardiomyocytes and consequently lead to significant loss of the contractile capacity of the heart. To repair functions of the injured heart, a great deal of research has attempted to develop regenerative medicine using pluripotent stem cell-based cardiomyocytes as cell therapy products. However, the efficiency of the current methods available for the cardiac differentiation of stem cells is insufficient for clinical settings. A comprehensive understanding of the mechanism involved in the cardiac differentiation of stem cells is necessary to improve the differentiation efficiency. To identify genes assosiated with cardiomyogenic potential, we isolated P19CL6 cell sublines possessing distinct properties in cardiomyogenesis and comprared their transcriptome profiles with those of mouse embryonal carcinoma P19 and P19CL6 cells. Total RNA isolated from undifferentiated EC cell strains (P19 cells, P19CL6 cells, and 4 P19CL6 sublines) using Affymetrix chips MOE430A and MOE430AB. CEL files unavailable.
2011-01-26 | E-GEOD-26875 | biostudies-arrayexpress
Project description:This a model from the article:
Modelling the Role of UCH-L1 on Protein Aggregation in
Age-Related Neurodegeneration.
Proctor CJ, Tangeman PJ, Ardley HC. PLoS One.
2010 Oct 6;5(10):e13175 20949132
,
Abstract:
Overexpression of the de-ubiquitinating enzyme UCH-L1 leads to inclusion formation in response to proteasome impairment. These inclusions contain components of the ubiquitin-proteasome system and α-synuclein confirming that the ubiquitin-proteasome system plays an important role in protein aggregation. The processes involved are very complex and so we have chosen to take a systems biology approach to examine the system whereby we combine mathematical modelling with experiments in an iterative process. The experiments show that cells are very heterogeneous with respect to inclusion formation and so we use stochastic simulation. The model shows that the variability is partly due to stochastic effects but also depends on protein expression levels of UCH-L1 within cells. The model also indicates that the aggregation process can start even before any proteasome inhibition is present, but that proteasome inhibition greatly accelerates aggregation progression. This leads to less efficient protein degradation and hence more aggregation suggesting that there is a vicious cycle. However, proteasome inhibition may not necessarily be the initiating event. Our combined modelling and experimental approach show that stochastic effects play an important role in the aggregation process and could explain the variability in the age of disease onset. Furthermore, our model provides a valuable tool, as it can be easily modified and extended to incorporate new experimental data, test hypotheses and make testable predictions.
To the extent possible under law, all copyright and related or neighbouring rights to this encoded model have been dedicated to the public domain worldwide. Please refer to CC0 Public Domain Dedication
for more information.
In summary, you are entitled to use this encoded model in absolutely any manner you deem suitable, verbatim, or with modification, alone or embedded it in a larger context, redistribute it, commercially or not, in a restricted way or not.
To cite BioModels Database, please use: Li C, Donizelli M, Rodriguez N, Dharuri H, Endler L, Chelliah V, Li L, He E, Henry A, Stefan MI, Snoep JL, Hucka M, Le Novère N, Laibe C (2010) BioModels Database: An enhanced, curated and annotated resource for published quantitative kinetic models. BMC Syst Biol., 4:92.
2024-09-02 | BIOMD0000000293 | BioModels